Literature DB >> 15906339

Quantitative apparent diffusion coefficients and T2 relaxation times in characterizing contrast enhancing brain tumors and regions of peritumoral edema.

Joonmi Oh1, Soonmee Cha, Ashley H Aiken, Eric T Han, Jason C Crane, Jeffrey A Stainsby, Graham A Wright, William P Dillon, Sarah J Nelson.   

Abstract

PURPOSE: To investigate the potential value and relationship of in vivo quantification of apparent diffusion coefficients (ADCs) and T2 relaxation times for characterizing brain tumor cellularity and tumor-related edema.
MATERIALS AND METHODS: A total of 26 patients with newly diagnosed gliomas, meningiomas, or metastases underwent diffusion-weighted and six-echo multisection T2-preparation imaging. Regions of interest (ROIs) were drawn on conventional MR images to include tumor (as defined by contrast agent enhancement) and immediate and peripheral edema. Areas of necrosis were excluded. Median values of ADCs and T2 in the ROIs were calculated.
RESULTS: ADCs for gliomas were similar to those for meningiomas or metastases in all regions. Tumor T2 values for gliomas (159.5+/-30.6 msec) were significantly higher than those for meningiomas or metastases (125.0+/-31.1 msec; P=0.005). Immediate-edema T2 values for meningiomas or metastases (226.0+/-44.1 msec) were significantly higher than those for gliomas (203.5+/-32.8 msec; P=0.033). Peripheral-edema T2 values for gliomas (219.5+/-41.9 msec) were similar to those for meningiomas or metastases (202.5+/-26.5 msec; P=0.377). Both immediate- and peritumoral-edema ADCs and T2 values were significantly higher than those in tumor for both tumor types. ADCs and T2 values from all regions correlated significantly for gliomas (r=0.95; P<0.0001) and for meningiomas or metastases (r=0.81; P<0.0001).
CONCLUSION: The higher immediate-edema T2 values for nonglial tumors than for gliomas suggest tumor-related edema (vasogenic vs. infiltrated) can be further characterized by using T2 values. There were significant correlations between ADC and T2 values. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15906339     DOI: 10.1002/jmri.20335

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  60 in total

1.  High-resolution magnetic resonance colonography and dynamic contrast-enhanced magnetic resonance imaging in a murine model of colitis.

Authors:  Devkumar Mustafi; Xiaobing Fan; Urszula Dougherty; Marc Bissonnette; Gregory S Karczmar; Aytekin Oto; John Hart; Erica Markiewicz; Marta Zamora
Journal:  Magn Reson Med       Date:  2010-04       Impact factor: 4.668

2.  Self-refocused adiabatic pulse for spin echo imaging at 7 T.

Authors:  Priti Balchandani; Mohammad Mehdi Khalighi; Gary Glover; John Pauly; Daniel Spielman
Journal:  Magn Reson Med       Date:  2011-09-27       Impact factor: 4.668

3.  Discrepant longitudinal volumetric and metabolic evolution of diffuse intrinsic Pontine gliomas during treatment: implications for current response assessment strategies.

Authors:  U Löbel; S Hwang; A Edwards; Y Li; X Li; A Broniscer; Z Patay
Journal:  Neuroradiology       Date:  2016-07-20       Impact factor: 2.804

4.  Simultaneous detection of resolved glutamate, glutamine, and gamma-aminobutyric acid at 4 T.

Authors:  Jiani Hu; Shaolin Yang; Yang Xuan; Quan Jiang; Yihong Yang; E Mark Haacke
Journal:  J Magn Reson       Date:  2006-12-22       Impact factor: 2.229

5.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Authors:  Tracy T Batchelor; A Gregory Sorensen; Emmanuelle di Tomaso; Wei-Ting Zhang; Dan G Duda; Kenneth S Cohen; Kevin R Kozak; Daniel P Cahill; Poe-Jou Chen; Mingwang Zhu; Marek Ancukiewicz; Maciej M Mrugala; Scott Plotkin; Jan Drappatz; David N Louis; Percy Ivy; David T Scadden; Thomas Benner; Jay S Loeffler; Patrick Y Wen; Rakesh K Jain
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

6.  Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival.

Authors:  Elke Hattingen; Alina Jurcoane; Keivan Daneshvar; Ulrich Pilatus; Michel Mittelbronn; Joachim P Steinbach; Oliver Bähr
Journal:  Neuro Oncol       Date:  2013-08-07       Impact factor: 12.300

7.  Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI.

Authors:  Benjamin M Ellingson; Albert Lai; Huytram N Nguyen; Phioanh L Nghiemphu; Whitney B Pope; Timothy F Cloughesy
Journal:  Clin Cancer Res       Date:  2015-04-21       Impact factor: 12.531

8.  Evaluation of brain tumor vessels specific contrast agents for glioblastoma imaging.

Authors:  Boguslaw Tomanek; Umar Iqbal; Barbara Blasiak; Abedelnasser Abulrob; Homam Albaghdadi; John R Matyas; Dragana Ponjevic; Garnette R Sutherland
Journal:  Neuro Oncol       Date:  2011-10-19       Impact factor: 12.300

9.  Differentiation between glioblastomas and solitary brain metastases using diffusion tensor imaging.

Authors:  Sumei Wang; Sungheon Kim; Sanjeev Chawla; Ronald L Wolf; Wei-Guo Zhang; Donald M O'Rourke; Kevin D Judy; Elias R Melhem; Harish Poptani
Journal:  Neuroimage       Date:  2008-10-07       Impact factor: 6.556

10.  Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging.

Authors:  Jinyuan Zhou; Jaishri O Blakeley; Jun Hua; Mina Kim; John Laterra; Martin G Pomper; Peter C M van Zijl
Journal:  Magn Reson Med       Date:  2008-10       Impact factor: 4.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.